VCELHealthcare · BiotechnologyThe 8 Wall Street analysts covering Vericel Corp. hold a median 12-month price target of $59 — +28.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Vericel Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Value (59): The shares cost a lot relative to the profits and assets behind them.
Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Vericel Corp. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on VCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +28.1% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | HC Wainwright & Co. | Maintains | Buy | $70 → $72 |
| 31 July 2026 | TD Cowen | Maintains | Buy | $55 → $58 |
| 31 July 2026 | Truist Securities | Reiterates | Buy | $54 → $58 |
| 28 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | $42 → $54 |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 27 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | Truist Securities | Maintains | Buy | — |
| 10 Nov 2025 | Truist Securities | Reiterates | Buy | — |
| 15 Oct 2025 | Truist Securities | Maintains | Buy | — |
| 17 Sept 2025 | BTIG | Downgrade | Neutral | — |
| 1 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 16 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 22 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 11 Apr 2025 | Truist Securities | Maintains | Buy | — |
| 3 Mar 2025 | Truist Securities | Reiterates | Buy | — |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 17% of US stocks
Cheaper than 16% of US stocks
Cheaper than 3% of US stocks
Higher than 74% of US stocks
Higher than 64% of US stocks
Higher than 86% of US stocks
Higher than 49% of US stocks
Higher than 66% of US stocks
Higher than 58% of US stocks
Higher than 62% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VCEL appears on the weeks it earns a place.
Vericel reported record second-quarter revenue and raised its full-year outlook, driven by growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Why it matters — The strong quarterly performance and upward revision to the full-year forecast signal sustained momentum in Vericel's core product lines and improving financial health.
Vericel Corporation held its Q2 2026 earnings conference call, and the transcript of that call was published by Seeking Alpha.
Why it matters — Investors tracking Vericel can review management's discussion of second-quarter performance and outlook as detailed in the earnings call transcript.
Vericel Corporation (VCEL) reported quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share, compared to a loss of $0.01 per share a year ago.
Why it matters — The earnings beat shows Vericel's quarterly performance exceeded analyst expectations, reversing an anticipated loss into a profit.
Vericel reported second quarter 2026 financial results with total revenue up 22% to $77.5 million, net income of $2.2 million, and free cash flow of $14.3 million. The company raised its full-year 2026 revenue guidance to $330–$340 million and announced a $200 million share repurchase program authorized by the board.
Why it matters — The raised revenue guidance and new share repurchase program signal stronger-than-expected business performance and management's confidence in the company's financial outlook.
The 8 Wall Street analysts covering Vericel Corp. have a median 12-month price target of $59, with estimates ranging from $55 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Vericel Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vericel Corp. 94 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Vericel Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +28.1% from the last close, and Ticker Nerd's factor model ranks Vericel Corp. 94 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vericel Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $72 over the next 12 months.
Vericel Corp. returned +29.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's primary purpose is to provide next-generation solutions that harness the power of a patient's own cells to repair damaged tissues and restore function.
The most recent item we track (MarketBeat, 30 July 2026): "Vericel Q2 Earnings Call Highlights". Vericel reported record second-quarter revenue and raised its full-year outlook, driven by growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's primary purpose is to provide next-generation solutions that harness the power of a patient's own cells to repair damaged tissues and restore function. Vericel specializes in treatments for sports medicine and severe burn care, with key products including MACI, a personalized autologous cellularized scaffold for knee cartilage repair, and Epicel, a permanent skin replacement for patients with extensive burn injuries. Vericel's products serve critical roles in the biotechnology and healthcare sectors, impacting clinical outcomes for patients experiencing serious musculoskeletal and skin injuries. With headquarters in Cambridge, Massachusetts, Vericel operates at the intersection of medical innovation and patient-focused care, contributing to advancements in cellular therapy technologies. Through collaborations with medical professionals and institutions, Vericel plays a significant role in enhancing the quality of life for individuals undergoing complex surgical procedures, leading the advancement of regenerative medicine by refining techniques to produce effective treatments with the potential to transform standard practices in patient care.
CEO Mr. Dominick C. Colangelo Esq. · 357 employees · United States · https://www.vcel.com